Study Comparing Peripheral Nerve Ultrasound and Electrodiagnostic Tests in Guillain-Barr Syndrome and CIDP Aiming to Aid Early Diagnosis, Predict Outcomes, and Distinguish Nerve Disorder Subtypes

What this Trial Is About

Researchers are investigating the use of neuromuscular ultrasound NMUS, a non-invasive diagnostic tool, in patients with Guillain Barr Syndrome GBS and Chronic Inflammatory Demyelinating Polyradiculoneuropathy CIDP. The study aims to see if nerve changes detected by ultrasound correspond to traditional electrodiagnostic tests and whether this method can help with early diagnosis, predict outcomes, and distinguish between different disease subtypes. Understanding these nerve alterations may improve diagnosis and patient care by revealing more about the disease progression and nerve damage. The study includes two groups patients diagnosed with immune-mediated peripheral nerve disorders GBS or CIDP and healthy individuals as controls. Participants will undergo serial nerve ultrasounds and nerve conduction studies NCS over a six-month period to observe nerve morphology, monitor changes, and assess recovery predictions. The study also compares findings between patient and healthy groups to better understand nerve alterations in these conditions. Participants will be involved in multiple assessments during the six months, including nerve ultrasound imaging and clinical evaluations. Researchers will measure nerve changes, correlate these with clinical scales, and track disease subtype distinctions. The study will monitor nerve alterations over time and compare them with healthy controls to identify meaningful differences. The total participation period is six months, during which safety and disease progression will be closely observed.

Our Study Aims to Determine if Nerve Alterations in Acute GBS and CIDP Detectable by Ultrasound Match Electrodiagnostic Findings and if This Method Aids Early Diagnosis, Predict Their Outcomes and Differentiate Between Axonal and Demyelinating Subtypes.